NuvoAir Announced Publication of Two Abstracts from the Royal Brompton Hospital, London, UK

Lucida Medical (Cambridge University Spin-out) Joins GE Healthcare Edison™ Accelerator Programme

Lucida Medical was invited to join the Edison Accelerator programme for its pioneering work in helping identify prostate cancer and its exceptional development team led by Prof Evis Sala and Dr Antony Rix, both highly experienced in artificial intelligence, or AI, medical technology.

Boston Scientific Exercises Option to Acquire Farapulse, Inc.

FARAPULSE Pulsed Field Ablation (PFA) System is a non-thermal ablation system for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias.  

​July 1, 2020

NuvoAir, a leading digital therapeutics company in respiratory health, announced the publication of two abstracts from the Royal Brompton Hospital, London, UK, demonstrating the clinical benefits of its platform in Cystic Fibrosis.

NuvoAir stated the abstracts, published in the June supplement of the Journal of Cystic Fibrosis, were originally submitted to the 2020 European Cystic Fibrosis Conference in Lyon, France, prior to its cancellation.

Led by Dr. Madge, the Royal Brompton CF team demonstrated a 30.9% reduction in the number of booked face-to-face consultations and a 39.8% reduction in urgent face-to-face consultations when delivering their adult CF service virtually using NuvoAir’s platform. The solution was well-accepted by patients and was rated 9.4 out of 10. Moreover, 43.9% of patients reported that they felt they were better able to understand their disease as a result of using NuvoAir. Self-reported medication adherence was also improved.

“The integration of digital therapeutics into routine clinical practice is starting to gather pace, particularly during the pandemic. Innovative clinicians, like Dr. Madge, are now utilizing innovative tools to transform their clinical services to be more efficient and cost-effective, without compromising quality of care or patient outcomes,” Lorenzo Consoli, CEO of NuvoAir, said. “Patients are responding positively to these digital tools too, largely as a result of the increased engagement they feel they gain with their clinical team. We look forward to helping the clinical community accelerate this journey and make digital therapeutics a standard in respiratory medicine.”

The NuvoAir respiratory platform allows patients to perform a lung function and symptom assessment in the comfort of their own home. These data can be easily shared with their clinical team and used by the patient to understand how their disease progresses over time. More importantly, this data can be accessed by clinical teams via NuvoAir’s digital platform to monitor patients’ respiratory health. NuvoAir’s platform can help predict worsening respiratory conditions, therefore, medical professionals can then focus on their most critical cases to help optimize their workflow.​

NuvoAir is used across over 30 hospitals globally to help patients with severe lung conditions such as cystic fibrosis, IPF, severe asthma and COPD to achieve better respiratory health. NuvoAir technology is also successfully used to support pharma companies and CROs to virtualize their studies in over 20 trials globally, as well as to simplify the diagnostic process in a clinical setting.​

spot_img

DON'T MISS

Trinity Health Names Mark LePage, M.D., as Senior Vice President of Medical Groups and Ambulatory Strategy

Prior to his time at IHA, LePage served as chief medical officer of Marshfield Clinic in Wisconsin

Jody Crane, MD Recognized by Modern Healthcare As One of the 50 Most Influential Clinical Executives

Dr. Crane’s work to streamline operations positioned and prepared TeamHealth and its clinicians to face the COVID-19 pandemic. Under Dr. Crane’s leadership, TeamHealth was able to maintain high levels of clinical quality throughout the rapidly changing COVID environment.

Hyperfine Adds Medtech Leader and Visionary Scott Huennekens as Executive Chairman

Mr. Huennekens’ public boards include Chairman of Acutus Medical (IPO August 2020); Chairman of Envista (IPO September 2019); and board member of Nuvasive. He also serves as a board member and past Chairman of the Medical Device Manufacturer’s Association (MDMA).

Subscribe to Medical Device News Magazine here.

Related Articles